ICON Public Limited Company Asset Resilience Ratio
ICON Public Limited Company asset resilience ratio. ICON Public Limited Company (IJF) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ICON Public Limited Company (IJF) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ICON Public Limited Company (2016–2024)
Asset resilience ratio of ICON Public Limited Company from 2016 to 2024. This chart shows how ICON Public Limited Company's Asset Resilience Ratio has changed over time. Read ICON Public Limited Company (IJF) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ICON Public Limited Company's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ICON Public Limited Company total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: ICON Public Limited Company maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
ICON Public Limited Company Industry Peers by Asset Resilience Ratio
Compare ICON Public Limited Company's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.16% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193 |
Diagnostics & Research | 70.50% |
|
Krsnaa Diagnostics Limited
NSE:KRSNAA |
Diagnostics & Research | 9.90% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
ICON Public Limited Company Asset Resilience Ratio by Year (2016–2024)
ICON Public Limited Company asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for ICON Public Limited Company.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | €0.00 ≈ $0.00 |
€16.88 Billion ≈ $19.73 Billion |
-- |
| 2023-12-31 | 0.01% | €1.95 Million ≈ $2.28 Million |
€16.99 Billion ≈ $19.86 Billion |
+0.00pp |
| 2022-12-31 | 0.01% | €1.71 Million ≈ $2.00 Million |
€17.26 Billion ≈ $20.17 Billion |
+0.00pp |
| 2021-12-31 | 0.01% | €1.71 Million ≈ $2.00 Million |
€17.39 Billion ≈ $20.33 Billion |
-0.04pp |
| 2020-12-31 | 0.05% | €1.73 Million ≈ $2.02 Million |
€3.44 Billion ≈ $4.02 Billion |
-1.66pp |
| 2019-12-31 | 1.71% | €49.63 Million ≈ $58.02 Million |
€2.91 Billion ≈ $3.40 Billion |
-0.84pp |
| 2018-12-31 | 2.54% | €59.91 Million ≈ $70.04 Million |
€2.35 Billion ≈ $2.75 Billion |
-1.07pp |
| 2017-12-31 | 3.61% | €77.59 Million ≈ $90.71 Million |
€2.15 Billion ≈ $2.51 Billion |
-0.11pp |
| 2016-12-31 | 3.73% | €68.05 Million ≈ $79.55 Million |
€1.83 Billion ≈ $2.13 Billion |
-- |
About ICON Public Limited Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical stu… Read more